Umbel replaces president Tom Miller, who’s served as interim chief since the departure of founder Janet Campbell last September to focus on new venture Dominion Medical. His resume includes stints at Hologic, where he spent 15 years, Direct Radiography, Sterling Diagnostic Imaging and DuPont (NYSE:DD).
“Tom [Umbel] is an acknowledged leader in the medical device industry with a strong track record in women’s health and diagnostic imaging,” said Dr. Harry Jacobson, chairman of MedCare Investment Funds, which owns a stake in Seno. “Tom’s track record of success in commercializing imaging technologies will be invaluable as we move closer to bringing the Imagio breast imaging system to market.”
“I am enthusiastic to be joining Seno at this time and have the opportunity to help deliver to clinicians and patients a tool that will allow for more precise and earlier diagnosis of breast cancer,” Umbel added. “The team at Seno has done a tremendous job developing this innovative opto-acoustic technology. This technology has the potential to provide clinicians with the information needed to determine whether a suspicious breast mass is malignant or not, while potentially helping patients avoid undergoing negative biopsy procedures. I am confident that we have the pieces in place to bring this non-invasive method for diagnosing breast cancer to market.”
Tandem Diabetes expands commercial team
Tandem Diabetes Care said it built out its commercial team with a pair of hires, naming former Adaptive Biotechnologies commercial chief Brian Hansen as EVP and CCO; and tapping ex-Rioko Pharmaceuticals () exec Lori Gildea as VP of sales.
C2 Therapeutics adds 5 to executive team
C2 Therapeutics said it lured 5 new executives from Varian, Covidien, BarrX and Johnson & Johnson and OptiMedica: Former Varian strategy guru Jennifer Lloyd Halsey; ex-Covidien sales VP Ryan Brennan; Lisa Bischel, a BarrX veteran, as marketing VP; former J&J exec Quentin Manley as Europe VP; and erstwhile OptiMedica finance director Linda Raggl as finance VP.